[通过IRAK1/4抑制向慢性髓性白血病干细胞的新疗法]
Yosuke Tanaka1, Toshio Kitamura2
1IRCMS, Kumamoto University.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|October 4, 2023
概括
向静止性慢性髓性白血病 (CML) 干细胞是治愈的关键. 将伊马替尼与IRAK1/4抑制剂结合,可以消除这些耐性CML干细胞,并增强T细胞的攻击.
科学领域:
- 血液学 血液学 血液学
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


